Tiziana Life Sciences Ltd TLSA
0.69 USD +0.07 (+11.03%)
At closeNov 6, 2026, 6:48 PM EST
0.68 -0.01 -1.28%
After hours · Nov 6, 6:48 PM ET
0.6204 Day range 0.6988
0.62 52-week range 1.82
- YTD
- -53.77%
- 1 year
- -61.73%
News
reuters.com Tiziana's experimental MS treatment meets main goals in mid-stage study Tiziana's experimental MS treatment meets main goals in mid-stage study
benzinga.com Tiziana Life Sciences Announces Topline Data In Phase 2a INFORM-MS Trial With Intranasal Foralumab In Patients With Na-SPMS; Trial Meets Dual Primary Endpoints Trial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET imaging in patients treated with 50 ug nasal foralumab as…
benzinga.com Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027 Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI)…